Executives in pharmaceuticals provided insider information on the price increases, gross margin, and revenue growth from 2023 and their targets for 2024. We analyzed their responses and uncovered several traits the high performing companies had in common. Discover those and other insights in our Pharmaceuticals Pricing Benchmarks white paper.
Some Key Insights:
- North American Pharmaceutical companies had higher net price realization over European Pharmaceutical companies
- Europe set higher price increase and revenue growth targets and realized greater growth
- High discounting in both regions has led to net price underperformance versus inflation
- Companies passing on less than 50% of costs attain ambitious growth targets while still realizing a significantly higher net price increase
